

Filed On Behalf Of:

Novartis AG

By:

Nicholas N. Kallas
NKallas@fchs.com
ZortressAfinitorIPR@fchs.com
(212) 218-2100

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

ARGENTUM PHARMACEUTICALS LLC,
Petitioner,

v.

NOVARTIS AG,
Patent Owner.

Case IPR2017-01063
Patent 9,006,224

WAIVER OF PATENT OWNER'S PRELIMINARY RESPONSE

Pursuant to 37 C.F.R. § 42.107(b), Patent Owner Novartis AG hereby elects to waive its preliminary response in this *Inter Partes* Review No. 2017-01063. As indicated in the Trial Practice Guide, no adverse inference should be taken by this election. *See* Office Trial Practice Guide, Fed. Reg. Vol. 77, No. 157 (2012) at Section II.C. This election shall not constitute a waiver or admission by Patent Owner with respect to any material set forth in the Petition.

Respectfully submitted,

Dated: June 29, 2017

/ Nicholas N. Kallas /
Nicholas N. Kallas
Registration No. 31,530
Lead Counsel for Patent Owner
FITZPATRICK, CELLA, HARPER
& SCINTO
1290 Avenue of the Americas
New York, NY 10104-3800
Tel. 212-218-2100

CERTIFICATE OF SERVICE

I certify that a copy of the foregoing Waiver Of Patent Owner's Preliminary Response was served on June 29, 2017 by causing it to be sent by email to counsel for Petitioner at the following email addresses:

Kevin Laurence (klaurence@lpiplaw.com)

Matthew Phillips (mphillips@lpiplaw.com)

Tyler C. Liu (tliu@agpharm.com)

Dated: June 29, 2017

/ Nicholas N. Kallas /
Nicholas N. Kallas
Registration No. 31,530
FITZPATRICK, CELLA, HARPER
& SCINTO
1290 Avenue of the Americas
New York, NY 10104-3800
Tel. 212-218-2100